Merck & Co., Inc. (MRK)
Merck licenses experimental HIV pill to generic makers in 129 countries
Merck said on Friday it signed seven voluntary licensing agreements with generic drug manufacturers to make and sell lower-cost versions of its experimental once-monthly oral HIV pill in 129 low- and lower-middle-income countries.
Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?
Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Merck (MRK) Declines More Than Market: Some Information for Investors
Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions
Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. Company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing further LDL-C reduction, with peak sales potential estimated at $5 billion by 2034, strengthening MRK's cardiometabolic portfolio.
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL cholesterol, with the launch expected in weeks.
The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipfendra, marks the first once-daily oral PCSK9 inhibitor cleared for adults with high LDL cholesterol, including heterozygous familial hypercholesterolemia.
New Cholesterol Pill, Earnings Growth Boost Merck Shares
Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.
FDA signs off on Merck's cholesterol-lowering pill — the first oral treatment of its kind
The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including those with hereditary forms of the disease, which causes elevated levels of LDL.
FDA Expands MRK & PFE's Keytruda-Padcev Combo Use in Bladder Cancer
Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
